WO2023114529A3 - Pharmacoactive formulations for delivery of psychedelic compounds - Google Patents
Pharmacoactive formulations for delivery of psychedelic compounds Download PDFInfo
- Publication number
- WO2023114529A3 WO2023114529A3 PCT/US2022/053291 US2022053291W WO2023114529A3 WO 2023114529 A3 WO2023114529 A3 WO 2023114529A3 US 2022053291 W US2022053291 W US 2022053291W WO 2023114529 A3 WO2023114529 A3 WO 2023114529A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psychedelic
- delivery
- pharmacoactive
- formulations
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000001337 psychedelic effect Effects 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007937 lozenge Substances 0.000 abstract 4
- 239000000654 additive Substances 0.000 abstract 2
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 239000008123 high-intensity sweetener Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002200 mouth mucosa Anatomy 0.000 abstract 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 abstract 1
- 239000000341 volatile oil Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Lozenges comprising ethyl cellulose and psychedelic compound s for rapid and efficient delivery of medical psychedelic compound s are provided. The lozenge is suitable for administration of the psychedelic compound (s) through the oral mucosa to the bloodstream. Embodiments of the lozenge are disclosed that comprise additives which alleviate other issues related to administration of psychedelic compounds. Additives disclosed include essential oils for flavoring, permeation enhancers, and high-intensity sweeteners. Methods for manufacture of the lozenges and its use in treatment of disease conditions are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163291333P | 2021-12-17 | 2021-12-17 | |
US63/291,333 | 2021-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023114529A2 WO2023114529A2 (en) | 2023-06-22 |
WO2023114529A3 true WO2023114529A3 (en) | 2023-10-26 |
Family
ID=86773427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/053291 WO2023114529A2 (en) | 2021-12-17 | 2022-12-17 | Pharmacoactive formulations for delivery of psychedelic compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023114529A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018089863A1 (en) * | 2016-11-11 | 2018-05-17 | Bennes, Inc. | Formulations for efficient delivery of cannabinoids |
US20210145851A1 (en) * | 2019-11-19 | 2021-05-20 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
-
2022
- 2022-12-17 WO PCT/US2022/053291 patent/WO2023114529A2/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018089863A1 (en) * | 2016-11-11 | 2018-05-17 | Bennes, Inc. | Formulations for efficient delivery of cannabinoids |
US20210145851A1 (en) * | 2019-11-19 | 2021-05-20 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
Non-Patent Citations (3)
Title |
---|
DESCALÇO N., MEDEIROS A.B., SANTOS C. FERNANDES, BORGES G.: "Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?", EUROPEAN PSYCHIATRY, vol. 64, no. S1, 13 August 2021 (2021-08-13), FR , pages S417 - S417, XP093103742, ISSN: 0924-9338, DOI: 10.1192/j.eurpsy.2021.1114 * |
MACCALLUM CAROLINE A., EADIE LAUREN, BARR ALASDAIR M., BOIVIN MICHAEL, LU SHAOHUA: "Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain", FRONTIERS IN PHARMACOLOGY, vol. 12, 1 January 2021 (2021-01-01), pages 1 - 9, XP093103747, DOI: 10.3389/fphar.2021.633168 * |
WELTMAN A. S., SACKLER A. M., PANDHI V., JOHNSON L.: "Behavior and endocrine effects of 3,4,5-trimethoxyamphetamine in male mice", EXPERIENTIA, vol. 32, no. 3, 1 March 1976 (1976-03-01), CH , pages 357 - 359, XP009549934, ISSN: 0014-4754, DOI: 10.1007/BF01940837 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023114529A2 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5693455B2 (en) | Treatment of inflammation and inflammatory pain in the mucosa using a carrier for treatment of long-term mucosal release bioadhesion | |
US8367703B2 (en) | Method of treating a sore throat | |
JP4669960B2 (en) | Oral or pharyngeal preparations containing local anesthetics | |
JPWO2012029913A1 (en) | Oral | |
JP2004161667A (en) | Crude drug-formulated pharmaceutical composition | |
JP5337430B2 (en) | Orally disintegrating tablets | |
JP2010138125A (en) | Quickly soluble nicotine-containing film preparation | |
WO2023114529A3 (en) | Pharmacoactive formulations for delivery of psychedelic compounds | |
US20060251731A1 (en) | Therapeutic herbal lozenge composition | |
RU2426529C2 (en) | Orally decomposing powder, containing cilostazol and mannitol | |
EP0225831B1 (en) | Use of hyperoxygenated oils for the manufacture of a medicament for the treatment of herpes | |
WO2012057103A1 (en) | Pharmaceutical composition | |
JP6324951B2 (en) | Drugs for dysphagia | |
EP1694295B1 (en) | Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability | |
JP7123205B2 (en) | Oral pharmaceutical composition | |
CA2444839A1 (en) | Ambroxol for the treatment of inflammation in the pharynx | |
EP1646373B1 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
Nogueira et al. | 44265 Oral coenzyme Q10: the new authority in skin aging. Results of a randomized, double-blind, placebo-controlled trial in elderly women | |
RU2782018C1 (en) | Remedy for those quitting smoking | |
RU2253442C1 (en) | Cheek pouch (transbuccal) pharmaceutical composition | |
JP2005162713A (en) | Composition for oral administration | |
WO2024097327A1 (en) | Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction | |
RU2216320C1 (en) | Agent "faringal" for prophylaxis and treatment of infectious- inflammatory disease of mouth-pharynx | |
EP2018868A1 (en) | Compositions for the treatment and prevention of vertigo and tinnitus including citicoline, ginkgo biloba extract and dimeric flavones of ginkgo biloba |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22908523 Country of ref document: EP Kind code of ref document: A2 |